Format

Send to

Choose Destination
Diabetes Res Clin Pract. 2015 Mar;107(3):309-19. doi: 10.1016/j.diabres.2015.01.016. Epub 2015 Jan 21.

C-peptide: new findings and therapeutic possibilities.

Author information

1
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Cebix AB, Stockholm, Sweden. Electronic address: john.wahren@ki.se.
2
Cebix AB, Stockholm, Sweden.

Abstract

Much new information on C-peptide physiology has appeared during the past 20 years. It has been shown that C-peptide binds specifically to cell membranes, elicits intracellular signaling via G-protein and Ca2+ -dependent pathways, resulting in activation and increased expression of endothelial nitric oxide synthase, Na+, K+ -ATPase and several transcription factors of importance for anti-inflammatory, anti-oxidant and cell protective mechanisms. Studies in animal models of diabetes and early clinical trials in patients with type 1 diabetes demonstrate that C-peptide in replacement doses elicits beneficial effects on early stages of diabetes-induced functional and structural abnormalities of the peripheral nerves, the kidneys and the retina. Much remains to be learned about C-peptide's mechanism of action and long-term clinical trials in type 1 diabetes subjects will be required to determine C-peptide's clinical utility. Nevertheless, even a cautious evaluation of the available evidence presents the picture of a bioactive endogenous peptide with therapeutic potential.

KEYWORDS:

Na(+), K(+)-ATPase; Nephropathy; Neuropathy; Reactive oxygen species; Retinopathy; eNOS

PMID:
25648391
DOI:
10.1016/j.diabres.2015.01.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center